The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary study

Vascular injury represents one of the most frequent lesions in systemic lupus erythematosus (SLE). The aim of the study was to assess the influence of anti-endothelial cell antibodies (AECAs) on the development of endothelial cell (EC) activation, dysfunction and subsequent vasculitis in women with...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology international 2022-05, Vol.42 (5), p.791-801
Main Authors: Cieślik, Paweł, Semik-Grabarczyk, Elżbieta, Hrycek, Antoni, Holecki, Michał
Format: Article
Language:English
Subjects:
Antibodies
Autoantibodies
Biomarkers
Blood vessels
Cardiovascular disease
Creatinine
Endothelium, Vascular
Female
Humans
Laboratories
Lupus
Lupus Erythematosus, Systemic
Medicine
Medicine & Public Health
Observational Research
Plasma
Proteins
Rheumatology
Vasculitis - pathology
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c375t-a68eb5ae4d9cc84000124904bbfd7486b5822372775fbf9547e830ee71c6f0703
cites cdi_FETCH-LOGICAL-c375t-a68eb5ae4d9cc84000124904bbfd7486b5822372775fbf9547e830ee71c6f0703
container_end_page 801
container_issue 5
container_start_page 791
container_title Rheumatology international
container_volume 42
creator Cieślik, Paweł
Semik-Grabarczyk, Elżbieta
Hrycek, Antoni
Holecki, Michał
description Vascular injury represents one of the most frequent lesions in systemic lupus erythematosus (SLE). The aim of the study was to assess the influence of anti-endothelial cell antibodies (AECAs) on the development of endothelial cell (EC) activation, dysfunction and subsequent vasculitis in women with SLE. Fifty six women with SLE were divided into 2 subgroups, i.e. subjects with positive AECAs (+) and those with negative AECAs (–). The control group consisted of 25 healthy women. Clinical characteristics, routine laboratory tests and circulating markers of EC activation/dysfunction, i.e. monocyte-chemotactic protein-1 (MCP-1), soluble E- and P-selectin, vascular and intercellular adhesion molecule-1 (sVCAM-1, sICAM-1), von Willebrand factor (vWF), pentraxin 3 (the marker of vasculitis) the indicator of procoagulant activity i.e. prothrombin fragment 1 + 2 (F1 + 2) were detected using ELISA and compared between patients with AECA (+), AECA (–) and control subgroups. Serum concentrations of AECAs in AECA(+), AECA(–) and control groups were 4.58 ± 2.97, 0.92 ± 0.50 and 0.72 ± 0.28 AU/ml, respectively ( p 
doi_str_mv 10.1007/s00296-022-05104-5
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2638940660</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638940660</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-a68eb5ae4d9cc84000124904bbfd7486b5822372775fbf9547e830ee71c6f0703</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EomXgBVggS2zKIuXGseOE3WhUaKVKbIrELnLim44rJw65Tqt5IN4Td6aFqgtWtuzvnPtzGHufw2kOoD8TgKjLDITIQOUgM_WCHeey0Flews-XT-5H7A3RDUCuyxJes6NCiUrWZXXMfl9tkbthMl3koedmjC7D0Ya4Re-M5x16v39tg3VI_GR9tlnTJx5GnhBu8RZ9mAYc9_LWh2D5LRKh59YM5jqZj3wy0SWC-J2LW047iji4jvtlWojjvEtOg4mBFvqyd53mVHxwo5l3nOJid2_Zq954wncP54r9-Hp2tTnPLr9_u9isL7Ou0CpmpqywVQalrbuukpAGFrIG2ba91bIqW1UJUWihterbvlZSY1UAos67sgcNxYqdHHynOfxakGIzOLpfgRkxLNSIsqhqCWmJCf34DL0Jyzym7hIl60oqmegVEweqmwPRjH0zzW5IczU5NPchNocQmxRisw-xUUn04cF6aQe0fyWPqSWgOACUvsZrnP_V_o_tH-fdqaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649845426</pqid></control><display><type>article</type><title>The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary study</title><source>Springer Nature</source><creator>Cieślik, Paweł ; Semik-Grabarczyk, Elżbieta ; Hrycek, Antoni ; Holecki, Michał</creator><creatorcontrib>Cieślik, Paweł ; Semik-Grabarczyk, Elżbieta ; Hrycek, Antoni ; Holecki, Michał</creatorcontrib><description>Vascular injury represents one of the most frequent lesions in systemic lupus erythematosus (SLE). The aim of the study was to assess the influence of anti-endothelial cell antibodies (AECAs) on the development of endothelial cell (EC) activation, dysfunction and subsequent vasculitis in women with SLE. Fifty six women with SLE were divided into 2 subgroups, i.e. subjects with positive AECAs (+) and those with negative AECAs (–). The control group consisted of 25 healthy women. Clinical characteristics, routine laboratory tests and circulating markers of EC activation/dysfunction, i.e. monocyte-chemotactic protein-1 (MCP-1), soluble E- and P-selectin, vascular and intercellular adhesion molecule-1 (sVCAM-1, sICAM-1), von Willebrand factor (vWF), pentraxin 3 (the marker of vasculitis) the indicator of procoagulant activity i.e. prothrombin fragment 1 + 2 (F1 + 2) were detected using ELISA and compared between patients with AECA (+), AECA (–) and control subgroups. Serum concentrations of AECAs in AECA(+), AECA(–) and control groups were 4.58 ± 2.97, 0.92 ± 0.50 and 0.72 ± 0.28 AU/ml, respectively ( p &lt;  0.001). The study showed significant increases in EC activation markers, i.e. MCP-1, sE-selectin, sVCAM-1 and F1 + 2 in SLE AECA(+) compared to SLE AECA(–) and control groups. However, the indicator of vasculitis (PTX3) was significantly lower in SLE AECA(+). Moreover, multivariate analysis of variance showed a positive correlation between AECAs and sE-selectin and sVCAM-1 levels, but not with PTX3. AECAs were involved in the initial stages of vascular damage in SLE, i.e. in EC activation and dysfunction. However, they did not play a role in the development of vasculitis.</description><identifier>ISSN: 1437-160X</identifier><identifier>ISSN: 0172-8172</identifier><identifier>EISSN: 1437-160X</identifier><identifier>DOI: 10.1007/s00296-022-05104-5</identifier><identifier>PMID: 35284968</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antibodies ; Autoantibodies ; Biomarkers ; Blood vessels ; Cardiovascular disease ; Creatinine ; Endothelium, Vascular ; Female ; Humans ; Laboratories ; Lupus ; Lupus Erythematosus, Systemic ; Medicine ; Medicine &amp; Public Health ; Observational Research ; Plasma ; Proteins ; Rheumatology ; Vasculitis - pathology ; Womens health</subject><ispartof>Rheumatology international, 2022-05, Vol.42 (5), p.791-801</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-a68eb5ae4d9cc84000124904bbfd7486b5822372775fbf9547e830ee71c6f0703</citedby><cites>FETCH-LOGICAL-c375t-a68eb5ae4d9cc84000124904bbfd7486b5822372775fbf9547e830ee71c6f0703</cites><orcidid>0000-0002-3723-3591 ; 0000-0002-3289-1050 ; 0000-0002-7871-528X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35284968$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cieślik, Paweł</creatorcontrib><creatorcontrib>Semik-Grabarczyk, Elżbieta</creatorcontrib><creatorcontrib>Hrycek, Antoni</creatorcontrib><creatorcontrib>Holecki, Michał</creatorcontrib><title>The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary study</title><title>Rheumatology international</title><addtitle>Rheumatol Int</addtitle><addtitle>Rheumatol Int</addtitle><description>Vascular injury represents one of the most frequent lesions in systemic lupus erythematosus (SLE). The aim of the study was to assess the influence of anti-endothelial cell antibodies (AECAs) on the development of endothelial cell (EC) activation, dysfunction and subsequent vasculitis in women with SLE. Fifty six women with SLE were divided into 2 subgroups, i.e. subjects with positive AECAs (+) and those with negative AECAs (–). The control group consisted of 25 healthy women. Clinical characteristics, routine laboratory tests and circulating markers of EC activation/dysfunction, i.e. monocyte-chemotactic protein-1 (MCP-1), soluble E- and P-selectin, vascular and intercellular adhesion molecule-1 (sVCAM-1, sICAM-1), von Willebrand factor (vWF), pentraxin 3 (the marker of vasculitis) the indicator of procoagulant activity i.e. prothrombin fragment 1 + 2 (F1 + 2) were detected using ELISA and compared between patients with AECA (+), AECA (–) and control subgroups. Serum concentrations of AECAs in AECA(+), AECA(–) and control groups were 4.58 ± 2.97, 0.92 ± 0.50 and 0.72 ± 0.28 AU/ml, respectively ( p &lt;  0.001). The study showed significant increases in EC activation markers, i.e. MCP-1, sE-selectin, sVCAM-1 and F1 + 2 in SLE AECA(+) compared to SLE AECA(–) and control groups. However, the indicator of vasculitis (PTX3) was significantly lower in SLE AECA(+). Moreover, multivariate analysis of variance showed a positive correlation between AECAs and sE-selectin and sVCAM-1 levels, but not with PTX3. AECAs were involved in the initial stages of vascular damage in SLE, i.e. in EC activation and dysfunction. However, they did not play a role in the development of vasculitis.</description><subject>Antibodies</subject><subject>Autoantibodies</subject><subject>Biomarkers</subject><subject>Blood vessels</subject><subject>Cardiovascular disease</subject><subject>Creatinine</subject><subject>Endothelium, Vascular</subject><subject>Female</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Observational Research</subject><subject>Plasma</subject><subject>Proteins</subject><subject>Rheumatology</subject><subject>Vasculitis - pathology</subject><subject>Womens health</subject><issn>1437-160X</issn><issn>0172-8172</issn><issn>1437-160X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAUhS0EomXgBVggS2zKIuXGseOE3WhUaKVKbIrELnLim44rJw65Tqt5IN4Td6aFqgtWtuzvnPtzGHufw2kOoD8TgKjLDITIQOUgM_WCHeey0Flews-XT-5H7A3RDUCuyxJes6NCiUrWZXXMfl9tkbthMl3koedmjC7D0Ya4Re-M5x16v39tg3VI_GR9tlnTJx5GnhBu8RZ9mAYc9_LWh2D5LRKh59YM5jqZj3wy0SWC-J2LW047iji4jvtlWojjvEtOg4mBFvqyd53mVHxwo5l3nOJid2_Zq954wncP54r9-Hp2tTnPLr9_u9isL7Ou0CpmpqywVQalrbuukpAGFrIG2ba91bIqW1UJUWihterbvlZSY1UAos67sgcNxYqdHHynOfxakGIzOLpfgRkxLNSIsqhqCWmJCf34DL0Jyzym7hIl60oqmegVEweqmwPRjH0zzW5IczU5NPchNocQmxRisw-xUUn04cF6aQe0fyWPqSWgOACUvsZrnP_V_o_tH-fdqaQ</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Cieślik, Paweł</creator><creator>Semik-Grabarczyk, Elżbieta</creator><creator>Hrycek, Antoni</creator><creator>Holecki, Michał</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3723-3591</orcidid><orcidid>https://orcid.org/0000-0002-3289-1050</orcidid><orcidid>https://orcid.org/0000-0002-7871-528X</orcidid></search><sort><creationdate>20220501</creationdate><title>The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary study</title><author>Cieślik, Paweł ; Semik-Grabarczyk, Elżbieta ; Hrycek, Antoni ; Holecki, Michał</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-a68eb5ae4d9cc84000124904bbfd7486b5822372775fbf9547e830ee71c6f0703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies</topic><topic>Autoantibodies</topic><topic>Biomarkers</topic><topic>Blood vessels</topic><topic>Cardiovascular disease</topic><topic>Creatinine</topic><topic>Endothelium, Vascular</topic><topic>Female</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Observational Research</topic><topic>Plasma</topic><topic>Proteins</topic><topic>Rheumatology</topic><topic>Vasculitis - pathology</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cieślik, Paweł</creatorcontrib><creatorcontrib>Semik-Grabarczyk, Elżbieta</creatorcontrib><creatorcontrib>Hrycek, Antoni</creatorcontrib><creatorcontrib>Holecki, Michał</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cieślik, Paweł</au><au>Semik-Grabarczyk, Elżbieta</au><au>Hrycek, Antoni</au><au>Holecki, Michał</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary study</atitle><jtitle>Rheumatology international</jtitle><stitle>Rheumatol Int</stitle><addtitle>Rheumatol Int</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>42</volume><issue>5</issue><spage>791</spage><epage>801</epage><pages>791-801</pages><issn>1437-160X</issn><issn>0172-8172</issn><eissn>1437-160X</eissn><abstract>Vascular injury represents one of the most frequent lesions in systemic lupus erythematosus (SLE). The aim of the study was to assess the influence of anti-endothelial cell antibodies (AECAs) on the development of endothelial cell (EC) activation, dysfunction and subsequent vasculitis in women with SLE. Fifty six women with SLE were divided into 2 subgroups, i.e. subjects with positive AECAs (+) and those with negative AECAs (–). The control group consisted of 25 healthy women. Clinical characteristics, routine laboratory tests and circulating markers of EC activation/dysfunction, i.e. monocyte-chemotactic protein-1 (MCP-1), soluble E- and P-selectin, vascular and intercellular adhesion molecule-1 (sVCAM-1, sICAM-1), von Willebrand factor (vWF), pentraxin 3 (the marker of vasculitis) the indicator of procoagulant activity i.e. prothrombin fragment 1 + 2 (F1 + 2) were detected using ELISA and compared between patients with AECA (+), AECA (–) and control subgroups. Serum concentrations of AECAs in AECA(+), AECA(–) and control groups were 4.58 ± 2.97, 0.92 ± 0.50 and 0.72 ± 0.28 AU/ml, respectively ( p &lt;  0.001). The study showed significant increases in EC activation markers, i.e. MCP-1, sE-selectin, sVCAM-1 and F1 + 2 in SLE AECA(+) compared to SLE AECA(–) and control groups. However, the indicator of vasculitis (PTX3) was significantly lower in SLE AECA(+). Moreover, multivariate analysis of variance showed a positive correlation between AECAs and sE-selectin and sVCAM-1 levels, but not with PTX3. AECAs were involved in the initial stages of vascular damage in SLE, i.e. in EC activation and dysfunction. However, they did not play a role in the development of vasculitis.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35284968</pmid><doi>10.1007/s00296-022-05104-5</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-3723-3591</orcidid><orcidid>https://orcid.org/0000-0002-3289-1050</orcidid><orcidid>https://orcid.org/0000-0002-7871-528X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1437-160X
ispartof Rheumatology international, 2022-05, Vol.42 (5), p.791-801
issn 1437-160X
0172-8172
1437-160X
language eng
recordid cdi_proquest_miscellaneous_2638940660
source Springer Nature
subjects Antibodies
Autoantibodies
Biomarkers
Blood vessels
Cardiovascular disease
Creatinine
Endothelium, Vascular
Female
Humans
Laboratories
Lupus
Lupus Erythematosus, Systemic
Medicine
Medicine & Public Health
Observational Research
Plasma
Proteins
Rheumatology
Vasculitis - pathology
Womens health
title The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A37%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20anti-endothelial%20cell%20antibodies%20(AECAs)%20on%20the%20development%20of%20blood%20vessel%20damage%20in%20patients%20with%20systemic%20lupus%20erythematosus:%20the%20preliminary%20study&rft.jtitle=Rheumatology%20international&rft.au=Cie%C5%9Blik,%20Pawe%C5%82&rft.date=2022-05-01&rft.volume=42&rft.issue=5&rft.spage=791&rft.epage=801&rft.pages=791-801&rft.issn=1437-160X&rft.eissn=1437-160X&rft_id=info:doi/10.1007/s00296-022-05104-5&rft_dat=%3Cproquest_cross%3E2638940660%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-a68eb5ae4d9cc84000124904bbfd7486b5822372775fbf9547e830ee71c6f0703%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2649845426&rft_id=info:pmid/35284968&rfr_iscdi=true